Myelodysplasia in the Wellington region 2002–2007: disease incidence and treatment patterns

Irwin, James; D'Souza, Alwyn; Johnson, Lambro A.; Carter, J.

doi:10.1111/j.1445-5994.2011.02443.x

Cited by 6 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent MDS cohort without such restriction, only 3 of 70 patients were younger than 40 years [15]. The overall incidence of MDS in the United States per 100,000 individuals aged 70–79 is 20.94 and in those less than 40 years only 0.14 [16].…”

Section: Resultsmentioning

confidence: 99%

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog

Natelson

Pyatt

2013

Advances in Hematology

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are clonal myeloid disorders characterized by progressive peripheral blood cytopenias associated with ineffective myelopoiesis. They are typically considered neoplasms because of frequent genetic aberrations and patient-limited survival with progression to acute myeloid leukemia (AML) or death related to the consequences of bone marrow failure including infection, hemorrhage, and iron overload. A progression to AML has always been recognized among the myeloproliferative disorders (MPD) but occurs only rarely among those with essential thrombocythemia (ET). Yet, the World Health Organization (WHO) has chosen to apply the designation myeloproliferative neoplasms (MPN), for all MPD but has not similarly recommended that all MDS become the myelodysplastic neoplasms (MDN). This apparent dichotomy may reflect the extremely diverse nature of MDS. Moreover, the term MDS is occasionally inappropriately applied to hematologic disorders associated with acquired morphologic myelodysplastic features which may rather represent potentially reversible hematological responses to immune-mediated factors, nutritional deficiency states, and disordered myelopoietic responses to various pharmaceutical, herbal, or other potentially myelotoxic compounds. We emphasize the clinical settings, and the histopathologic features, of such AMD that should trigger a search for a reversible underlying condition that may be nonneoplastic and not MDS.

show abstract

Section: Resultsmentioning

confidence: 99%

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog

Natelson

Pyatt

2013

Advances in Hematology

View full text Add to dashboard Cite

show abstract

“…The incidence of MDS, which still remains inaccurate, has been reported to vary-3.2/10 5 [1] and 7.7/10 5 [2] in France, 6/10 5 [3] and 12.6/10 5 [4] in the UK, 3.3/10 5 in the USA [5], 1.24/ 10 5 in European cancer registries [6], 2.75/10 5 in New Zealand [7], and 1.0/10 5 in Japan [8]. The reported incidence differs greatly among countries (Table 1).…”

mentioning

confidence: 99%

First report of incidence of adult myelodysplastic syndrome in China

Wang

et al. 2011

Ann Hematol

View full text Add to dashboard Cite

“…Hiwase et al 18 "RBC transfusion dependent patients had inferior overall survival compared to RBC transfusion independent patients" "RBC transfusion dependence was an independent adverse prognostic markers" Irwin et al 19 "Despite the observed increase in serum ferritin over the course of this study, and despite not receiving iron chelation therapy, the majority of transfusion dependent MDS patients did not develop a clinical syndrome of iron overload." Kim et al 21 "patients with MDS (…) requiring chronic transfusions have higher RBC alloimmunization rates than other transfused patient populations."…”

Section: Survivalmentioning

confidence: 82%

“…Nine studies reported outcomes relating to iron overload and its complications. 10,12,19,24,27,30,32,37,43 Three studies found an increased risk of iron overload complications among transfused MDS patients, including presentations of cardiomyopathy/heart failure, conduction disorders, diabetes and liver disease. 10,27,30 Two studies examined magnetic resonance imaging evidence of iron deposition with conflicting results about the correlation between liver iron and transfusion burden.…”

Section: Clinical Complicationsmentioning

confidence: 99%

Red blood cell transfusion in myelodysplastic syndromes: A systematic review

Kaka

Jahangirnia

Beauregard

et al. 2021

Transfusion Medicine

View full text Add to dashboard Cite

Patients with myelodysplastic syndrome (MDS) frequently receive red blood cell (RBC) transfusions for anaemia resulting from ineffective erythropoiesis. While RBC transfusions may rapidly increase haemoglobin values, their impact on clinical and health services outcomes in MDS patients has not previously been summarized. We conducted a systematic review of the literature to evaluate risks and benefits of RBC transfusions in MDS patients. We searched electronic databases (MEDLINE, Embase, CENTRAL, CINAHL) from inception through June 4, 2021 to identify studies reporting data on RBC transfusions in MDS patients. Full text publications that assessed RBC transfusions as an intervention and reported at least one clinical, laboratory, or healthcare outcome associated with transfusion were included. Study characteristics, transfusion information and transfusion-related outcomes were extracted and reported. We identified 1243 original studies, of which 38 met eligibility requirements and were included.Fourteen reported on survival following diagnosis of MDS, with the majority reporting poorer survival among patients receiving or requiring more frequent transfusions. Nine reported on transfusion-related iron overload and its complications. Other outcomes included rates of allo/autoimmunization and adverse transfusion reactions, and healthcare costs incurred by patients with a greater transfusion burden. Only two studies reported on symptom relief following transfusion. This review underscores transfusion dependence as a negative prognostic factor for MDS patients and highlights the paucity of evidence surrounding quality of life and symptom-related outcomes following RBC transfusions in this population. Further study of patient-important outcomes associated with transfusion in MDS patients is warranted to improve therapeutic recommendations and inform resource allocation.

show abstract

Myelodysplasia in the Wellington region 2002–2007: disease incidence and treatment patterns

Cited by 6 publications

References 33 publications

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog

First report of incidence of adult myelodysplastic syndrome in China

Red blood cell transfusion in myelodysplastic syndromes: A systematic review

Contact Info

Product

Resources

About